145 related articles for article (PubMed ID: 20709215)
1. Rimonabant: obituary for a wonder drug.
Boekholdt SM; Peters RJ
Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
[No Abstract] [Full Text] [Related]
2. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
3. Effect of rimonabant on weight reduction and cardiovascular risk.
van Oosten B; Killestein J; Polman Ch
Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
[No Abstract] [Full Text] [Related]
4. Effect of rimonabant on weight reduction and cardiovascular risk.
Hirschel B
Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
[No Abstract] [Full Text] [Related]
5. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
[No Abstract] [Full Text] [Related]
6. [New drugs; rimonabant].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
[No Abstract] [Full Text] [Related]
8. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
9. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
10. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
[No Abstract] [Full Text] [Related]
11. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topol EJ; Bousser MG; Fox KA; Creager MA; Despres JP; Easton JD; Hamm CW; Montalescot G; Steg PG; Pearson TA; Cohen E; Gaudin C; Job B; Murphy JH; Bhatt DL;
Lancet; 2010 Aug; 376(9740):517-23. PubMed ID: 20709233
[TBL] [Abstract][Full Text] [Related]
12. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
13. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
[TBL] [Abstract][Full Text] [Related]
14. Effect of rimonabant on weight reduction and cardiovascular risk.
Astrup A
Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
[No Abstract] [Full Text] [Related]
15. [Rimonabant. Risk of depression has not been finally clarified].
Kreutzkamp B
Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
[No Abstract] [Full Text] [Related]
16. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
[No Abstract] [Full Text] [Related]
17. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
18. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
19. Effect of rimonabant on weight reduction and cardiovascular risk.
Esposito K; Giugliano D
Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931
[No Abstract] [Full Text] [Related]
20. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Tonstad S
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
